期刊文献+

金属硫蛋白和瑞舒伐他汀对ApoE基因缺陷小鼠主动脉α-SMA表达的影响

下载PDF
导出
摘要 目的:探讨金属硫蛋白和HMG-CoA还原酶抑制剂瑞舒伐他汀对ApoE基因缺陷小鼠主动脉粥样硬化及α-SMA表达的影响。方法:30只6周龄雄性ApoE基因缺陷小鼠随机分为高脂模型组、瑞舒伐他汀组、金属硫蛋白组、正常对照组,13周后对比总胆固醇(TCH)、甘油三酯(TG)、低密度脂蛋白(LDL-C)的水平,以及肝肾功能(AST、ALT、BUN、CRE)及肌酸磷酸激酶(CK、CK-MB)等生化指标,观察主动脉形态学变化和血管壁斑块组织变化,定性分析α-SMA表达强度的变化。结果:6周龄ApoE基因缺陷雄性小鼠喂养13周后,与阳性对照组比较,瑞舒伐他汀组,血清中总胆固醇(TCH)、甘油三酯(TG)、低密度脂蛋白(LDL)水平显著降低,有统计学差异(P<0.05),金属硫蛋白组TCH、TG、LDL水平无统计学差异(P>0.05)。金属硫蛋白和瑞舒伐他汀组肝肾功能和肌酸磷酸激酶与阳性对照组无统计学差异(P>0.05)。阳性对照组主动脉管壁、内膜明显增厚,血管壁组织α-SMA表达较阴性对照组明显增加;瑞舒伐他汀和金属硫蛋白组主动脉管壁、内膜增厚减轻,血管壁组织α-SMA表达较阳性对照组减少。结论:瑞舒伐他汀降低血脂作用明显,金属硫蛋白对血脂无明显影响;瑞舒伐他汀及金属硫蛋白均可以减少动脉粥样硬化病变中α-SMA表达,二者抗动脉粥样硬化作用可能与阻止VSMC向动脉粥样硬化斑块中迁移有关。
出处 《中国美容医学》 CAS 2012年第11X期26-27,共2页 Chinese Journal of Aesthetic Medicine
  • 相关文献

参考文献1

二级参考文献22

  • 1Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
  • 2LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
  • 3Pedersen TR, Faergeman O, Kastelein J J, et al; Incremental Decrease in End Points Through Aggressive Lipid Lowedng (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study:a randomized controlled trial. JAMA. 2005;294:2437-2445.
  • 4Grundy SM, Cleeman JI, Merz CN, et al; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ Guidelines. J Am Coll Cardiol. 2004;44:720-732.
  • 5Blankenhom DH, Azen SP, Kramsch DM, et al;MARS Research Group. Coronary angiographic changes with Iovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med.1993;119:969-976.
  • 6Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed be serial quantitaUve arteriography: the Canadian Coronary Atherosclerosis Intervention Trial(CCAIT). Circulation. 1994;89:959-968.
  • 7Jukema JW, Bruschke AV, van Boven A J, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
  • 8Pitt B, Mancini GB, Ellis SG, Rosrnan HS, Park J-S,McGovem ME. Pravastatin limitaUon of atherosclerosis in the coronary arteries (PLAC Ⅰ): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-1139.
  • 9Brown G, Albers J J, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipidlowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
  • 10MAAS Study Group. Effect of simvastatin on coronary atheroma: the Multicentre Anti-atheroma Study( MAAS). Lancet. 1994;344:633 -638.

共引文献345

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部